Cardiff Oncology (CRDF)
Market Price (4/23/2026): $1.73 | Market Cap: $116.7 MilSector: Health Care | Industry: Biotechnology
Cardiff Oncology (CRDF)
Market Price (4/23/2026): $1.73Market Cap: $116.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -49% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -57% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -49 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8256% Expensive valuation multiplesP/SPrice/Sales ratio is 197x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 960% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6395%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6398% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -43% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 32.33, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27% Key risksCRDF key risks include [1] an over-reliance on the clinical and regulatory success of its single primary drug candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -49% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -57% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -49 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8256% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 197x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 960% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6395%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6398% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -43% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 32.33, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27% |
| Key risksCRDF key risks include [1] an over-reliance on the clinical and regulatory success of its single primary drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Executive Leadership Changes and Resulting Uncertainty.
Cardiff Oncology experienced a significant stock drop, plummeting approximately 31-34% on January 28, 2026, following the announcement that its CEO, Dr. Mark Erlander, and CFO, James Levine, were stepping down. This unexpected leadership overhaul created investor unease and concerns regarding the company's future strategic direction during its transition to late-stage clinical development.
2. Market Skepticism Despite Positive Phase 2 Clinical Data.
Despite reporting a positive update from its Phase 2 CRDF-004 trial in January 2026, where the 30 mg onvansertib arm demonstrated a confirmed objective response rate (ORR) of 72.2% compared to 43.2% for standard of care in RAS-mutated metastatic colorectal cancer, and a significant improvement in progression-free survival (HR: 0.37, p<0.05), the stock's overall decline persisted. This suggests that while the data was positive, the market may have factored in previous muted reactions to clinical updates or held a skeptical view on the program's long-term commercialization or the company's ability to finance future large-scale trials.
Show more
Stock Movement Drivers
Fundamental Drivers
The -38.4% change in CRDF stock from 12/31/2025 to 4/22/2026 was primarily driven by a -47.6% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.81 | 1.73 | -38.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 18.4% |
| P/S Multiple | 375.1 | 196.7 | -47.6% |
| Shares Outstanding (Mil) | 67 | 67 | -0.8% |
| Cumulative Contribution | -38.4% |
Market Drivers
12/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| CRDF | -38.4% | |
| Market (SPY) | -5.4% | 26.4% |
| Sector (XLV) | -5.4% | 43.9% |
Fundamental Drivers
The -16.0% change in CRDF stock from 9/30/2025 to 4/22/2026 was primarily driven by a -21.6% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.06 | 1.73 | -16.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 8.6% |
| P/S Multiple | 251.0 | 196.7 | -21.6% |
| Shares Outstanding (Mil) | 67 | 67 | -1.3% |
| Cumulative Contribution | -16.0% |
Market Drivers
9/30/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| CRDF | -16.0% | |
| Market (SPY) | -2.9% | 36.1% |
| Sector (XLV) | 5.6% | 37.0% |
Fundamental Drivers
The -44.9% change in CRDF stock from 3/31/2025 to 4/22/2026 was primarily driven by a -21.0% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.14 | 1.73 | -44.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | -13.3% |
| P/S Multiple | 248.9 | 196.7 | -21.0% |
| Shares Outstanding (Mil) | 54 | 67 | -19.6% |
| Cumulative Contribution | -44.9% |
Market Drivers
3/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| CRDF | -44.9% | |
| Market (SPY) | 16.3% | 27.4% |
| Sector (XLV) | 1.6% | 36.6% |
Fundamental Drivers
The 4.8% change in CRDF stock from 3/31/2023 to 4/22/2026 was primarily driven by a 53.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.65 | 1.73 | 4.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 53.6% |
| P/S Multiple | 190.3 | 196.7 | 3.4% |
| Shares Outstanding (Mil) | 45 | 67 | -34.0% |
| Cumulative Contribution | 4.8% |
Market Drivers
3/31/2023 to 4/22/2026| Return | Correlation | |
|---|---|---|
| CRDF | 4.8% | |
| Market (SPY) | 63.3% | 20.9% |
| Sector (XLV) | 18.4% | 21.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CRDF Return | -67% | -77% | 6% | 193% | -35% | -41% | -91% |
| Peers Return | -7% | 32% | 41% | -1% | 2% | 12% | 94% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 88% |
Monthly Win Rates [3] | |||||||
| CRDF Win Rate | 25% | 42% | 50% | 58% | 33% | 50% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 67% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CRDF Max Drawdown | -72% | -81% | -31% | -1% | -55% | -47% | |
| Peers Max Drawdown | -25% | 0% | -2% | -3% | -23% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ALPS, DFTX, EIKN, GENB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/22/2026 (YTD)
How Low Can It Go
| Event | CRDF | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -95.1% | -25.4% |
| % Gain to Breakeven | 1938.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -66.1% | -33.9% |
| % Gain to Breakeven | 194.7% | 51.3% |
| Time to Breakeven | 70 days | 148 days |
| 2018 Correction | ||
| % Loss | -99.4% | -19.8% |
| % Gain to Breakeven | 17008.9% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -72.5% | -56.8% |
| % Gain to Breakeven | 263.3% | 131.3% |
| Time to Breakeven | 1,236 days | 1,480 days |
Compare to VRTX, ALPS, DFTX, EIKN, GENB
In The Past
Cardiff Oncology's stock fell -95.1% during the 2022 Inflation Shock from a high on 1/14/2021. A -95.1% loss requires a 1938.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cardiff Oncology (CRDF)
AI Analysis | Feedback
Here are 1-2 brief analogies for Cardiff Oncology (CRDF):
- Think of it as an early-stage Amgen or Genentech, exclusively focused on developing new cancer therapies.
- It's like a highly focused R&D lab for cancer drugs, akin to a dedicated department within a major pharma company like Merck or Pfizer, but operating independently.
AI Analysis | Feedback
- onvansertib: An oral selective Polo-like Kinase 1 Inhibitor (PLK1) being developed as an anti-cancer therapeutic.
- CY140: An inhibitor of PLK1, PLK2, and PLK3, currently in early-stage clinical trials for solid tumors and leukemias.
- TROV-054: A drug candidate in Phase 1b/2 clinical trials for metastatic colorectal cancer, specifically in combination with FOLFIRI and bevacizumab.
- TROV-053: A drug candidate in Phase II clinical trials for metastatic castration-resistant prostate cancer, in combination with Zytiga.
AI Analysis | Feedback
Cardiff Oncology (CRDF) is a clinical-stage oncology company focused on developing medicine treatments for cancer patients.
Based on the provided information, the company primarily serves pharmaceutical manufacturers.
As a clinical-stage company, Cardiff Oncology develops drug candidates through various phases of clinical trials. The description does not specify the names of any particular pharmaceutical manufacturers that are current major customers. This is typical for clinical-stage companies, as their business model often involves developing drugs to a certain point and then seeking partnerships, licensing agreements, or acquisitions by larger pharmaceutical companies for further development, manufacturing, and commercialization.
AI Analysis | Feedback
nullAI Analysis | Feedback
Mani Mohindru, PhD Interim Chief Executive Officer
Mani Mohindru has served as interim Chief Executive Officer of Cardiff Oncology since January 2026 and has been a director since 2021. She was most recently the CEO of Novasanta, an oncology-focused biotech company, and a Director on the Board of CytomX, Inc. (Nasdaq: CTMX). Dr. Mohindru previously held executive roles at several biotechnology companies, including Chief Executive Officer of CereXis, Inc., Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), and Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS). She also co-founded Roshon Therapeutics, a private biotechnology company focused on developing novel therapies for cancer and inflammatory diseases. Earlier in her career, Dr. Mohindru was an equity research analyst covering the biotechnology sector at UBS, Credit Suisse, and ThinkEquity.
Brigitte Lindsay Chief Accounting Officer
Brigitte Lindsay has served as Chief Accounting Officer of Cardiff Oncology since January 2026, overseeing the finance function. She has been with the company for over 14 years and was most recently the Senior Vice President of Finance. Prior to Cardiff Oncology, Ms. Lindsay served as Controller for AviaraDx, both before and after its acquisition by bioMérieux. She was also a Manager of Financial Reporting and Analysis at Carl Zeiss Meditec.
Roger Sidhu, MD Chief Medical Officer
Dr. Roger Sidhu was appointed Chief Medical Officer of Cardiff Oncology in June 2025. He is an accomplished drug developer with over 20 years of oncology leadership and clinical experience. Dr. Sidhu was most recently Acting CEO and Chief Medical Officer at Treadwell Therapeutics, a privately held biotechnology company where he was responsible for advancing a portfolio of small molecules for solid tumors and hematologic malignancies. Previously, he spent nearly 10 years at Amgen in roles of increasing responsibility in the Hematology/Oncology therapeutic area, where he advanced multiple therapeutic candidates and led several Phase 3 clinical trials for panitumumab (Vectibix®).
Tod Smeal, PhD Chief Scientific Officer
Dr. Tod Smeal has served as Chief Scientific Officer of Cardiff Oncology since January 2022. Prior to joining Cardiff Oncology, he was CSO at Hexagon Bio from 2020 to 2021, and CSO of Cancer Biology at Eli Lilly and Company from 2015 to 2020. Dr. Smeal also held positions as Director at the Oncology Research Unit of Pfizer (2003-2015) and Senior Group Leader at the SUGEN site of Pharmacia and Upjohn and SUGEN (1998-2003). He has played key leadership roles in delivering approximately 20 first-in-human drugs/new medical entities and several FDA-approved or soon-to-be approved drugs, including Lorbrena, Xalkori, Vizimpro, and Nirogacestat.
AI Analysis | Feedback
```htmlFor Cardiff Oncology (CRDF), the key risks to the business are primarily centered around its status as a clinical-stage biotechnology company with a limited pipeline.
- Clinical Trial Failure and Regulatory Approval Challenges: The most significant risk for Cardiff Oncology stems from the inherent uncertainties of clinical trials and the subsequent regulatory approval process. The company's valuation is heavily dependent on the successful progression and outcomes of its lead drug candidate, onvansertib, through various clinical phases, particularly the pivotal Phase 3 trials. There are no guarantees that future clinical trials will be completed successfully, demonstrate sufficient efficacy and safety, or lead to regulatory approval for any indication. Failures, delays, or unexpected side effects during these trials could severely impact the company's prospects and valuation.
- Need for Additional Financing and Financial Health: As a clinical-stage company without commercial product revenue, Cardiff Oncology relies on external funding to finance its extensive and expensive research and development activities and clinical trials. The company has reported negative operating and net margins, and its Altman Z-Score indicates a potential risk of bankruptcy. While it currently has a cash runway into Q1 2027, advancing onvansertib through late-stage clinical development, especially Phase 3, will necessitate substantial additional capital. The need for future capital raises could lead to dilution for existing shareholders.
- Reliance on a Single Lead Drug Candidate: Cardiff Oncology's business model is largely concentrated on the success of a single lead asset, onvansertib. Although the company is investigating onvansertib for multiple cancer indications (including metastatic colorectal cancer, prostate cancer, pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer), its pipeline lacks diversity with other approved or late-stage commercialized products. This single-asset dependency means that any significant setback or failure related to onvansertib could have a disproportionately severe impact on the company's overall viability and value.
AI Analysis | Feedback
nullAI Analysis | Feedback
Cardiff Oncology (symbol: CRDF) operates in several significant addressable markets for its oncology drug candidates. The main products and their corresponding market sizes are detailed below, specifying the region for each market valuation.
Metastatic Colorectal Cancer (mCRC)
The global market for metastatic colorectal cancer treatment was estimated to be valued at approximately USD 10.95 billion in 2025 and is projected to reach USD 19.13 billion by 2032. Other estimates indicate the global market for metastatic colorectal cancer treatment was valued at USD 7.68 billion in 2025 and is predicted to grow to USD 19.86 billion by 2035. The market is driven by increasing incidence of colorectal cancer worldwide and advancements in targeted therapies and immunotherapy. In the United States, the mCRC market accounted for roughly 45% of the total market size across the seven major markets in 2024, which collectively exceeded USD 13 billion.
Solid Tumors
The global solid tumor therapeutics market reached an estimated USD 210.46 billion in 2024 and is projected to grow to USD 408.47 billion by 2033. Another estimate places the global solid tumor cancer treatment market size at USD 362.21 billion in 2024, with a projection to reach USD 1557.42 billion by 2032. The North American region holds a dominant position in this market. Specifically, the U.S. solid tumor therapeutics market reached USD 20 billion in 2022 and is expected to grow to USD 45 billion by 2028.
Leukemias
The global leukemia therapeutics market size was calculated at USD 20.23 billion in 2025 and is projected to reach around USD 42.90 billion by 2035. North America dominated the leukemia therapeutics market revenue shares in 2025. The U.S. leukemia therapeutics market was estimated at USD 7.23 billion in 2024 and is projected to reach USD 13.07 billion by 2033.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The global metastatic castration-resistant prostate cancer therapeutics market size was valued at USD 21.04 billion in 2025 and is projected to grow to USD 91.85 billion by 2034. The market is expanding due to the rising prevalence of prostate cancer and increasing demand for treatment. The total mCRPC market size across the seven major markets (United States, EU4, and Japan) was estimated at nearly USD 6.8 billion in 2023. The United States accounted for approximately 64% of the total mCRPC market share within the 7MM in 2023, with its market alone valued at approximately USD 4.4 billion.
AI Analysis | Feedback
1. Advancement of Onvansertib into Registrational Trials for First-Line RAS-Mutated Metastatic Colorectal Cancer (mCRC): Cardiff Oncology has reported positive Phase 2 clinical trial results for its lead drug candidate, onvansertib, in combination with standard of care for first-line RAS-mutated mCRC. The company plans to initiate a registrational program for onvansertib in this indication later in 2026, pending finalization of the trial design with the FDA. While widespread commercialization for onvansertib is anticipated beyond the 2-3 year timeframe, successful progression into and through registrational trials is expected to trigger significant milestone payments from existing or future strategic partnerships, contributing to revenue growth.
2. Expansion of Onvansertib's Clinical Indications: Beyond mCRC, onvansertib is also being evaluated in investigator-initiated studies for other cancers, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). Promising monotherapy clinical results for CMML were recently presented in December 2025. Positive clinical advancements in these additional indications are expected to open avenues for new development collaborations, licensing deals, or non-dilutive funding, thereby contributing to future revenue growth through upfront payments or milestone achievements within the 2-3 year period.
3. Strategic Partnerships and Collaborations: Cardiff Oncology has an existing collaboration with Pfizer, which includes a prior investment and the right of first access to data. As onvansertib and other pipeline candidates advance through clinical development, new or expanded strategic partnerships are anticipated. These collaborations are expected to generate revenue through upfront payments, research funding, and milestone payments tied to clinical, regulatory, and commercial achievements, providing crucial capital for further development and contributing to the company's revenue growth.
AI Analysis | Feedback
Share Repurchases
Cardiff Oncology has not reported any significant share repurchase programs or activities in the last 3-5 years.
Share Issuance
- The number of outstanding shares for Cardiff Oncology increased from 41.96 million in 2021 to 68.36 million in 2026, with a significant increase of 48.89% between 2023 (44.68 million) and 2024 (66.52 million).
- In February 2025, Cardiff Oncology completed a $40 million underwritten registered direct offering, with participation from new and existing healthcare-dedicated investors, which strengthened its financial position.
- Other financing activities contributed $53.8 million in 2024 and $35.5 million in 2021, likely including proceeds from share issuances.
Inbound Investments
- The company received a $40 million investment from biotech specialist investors through an underwritten registered direct offering as of February 2025.
Outbound Investments
There is no available information indicating that Cardiff Oncology made any significant outbound investments in other companies or acquisitions in the last 3-5 years.
Capital Expenditures
- Capital expenditures were relatively low, reported as -$0.1 million in 2024, -$0.6 million in 2023, and -$1.0 million in 2022.
- In the last 12 months, capital expenditures were approximately -$44,000.
- While specific future capital expenditures were not detailed, the company's operating expenses and cash usage are primarily focused on advancing its research and development priorities, particularly its lead clinical trial program for onvansertib.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Cardiff Oncology Earnings Notes | 12/16/2025 | |
| Would You Still Hold Cardiff Oncology Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CRDF.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.31 |
| Mkt Cap | 55.6 |
| Rev LTM | 1 |
| Op Inc LTM | -49 |
| FCF LTM | -38 |
| FCF 3Y Avg | -36 |
| CFO LTM | -38 |
| CFO 3Y Avg | -36 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -2.2% |
| Rev Chg 3Y Avg | 14.1% |
| Rev Chg Q | 35.2% |
| QoQ Delta Rev Chg LTM | 10.4% |
| Op Inc Chg LTM | -0.6% |
| Op Inc Chg 3Y Avg | -7.2% |
| Op Mgn LTM | -4,109.2% |
| Op Mgn 3Y Avg | -4,100.1% |
| QoQ Delta Op Mgn LTM | 1,251.0% |
| CFO/Rev LTM | -3,182.4% |
| CFO/Rev 3Y Avg | -3,028.9% |
| FCF/Rev LTM | -3,185.8% |
| FCF/Rev 3Y Avg | -3,053.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 55.6 |
| P/S | 103.0 |
| P/Op Inc | 11.0 |
| P/EBIT | 10.7 |
| P/E | 12.8 |
| P/CFO | 13.7 |
| Total Yield | -17.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -13.1% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.9% |
| 3M Rtn | -5.5% |
| 6M Rtn | 0.8% |
| 12M Rtn | -5.9% |
| 3Y Rtn | 9.9% |
| 1M Excs Rtn | -10.3% |
| 3M Excs Rtn | -9.3% |
| 6M Excs Rtn | -5.0% |
| 12M Excs Rtn | -43.1% |
| 3Y Excs Rtn | -63.2% |
Price Behavior
| Market Price | $1.73 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/27/2004 | |
| Distance from 52W High | -61.1% | |
| 50 Days | 200 Days | |
| DMA Price | $1.73 | $2.31 |
| DMA Trend | down | down |
| Distance from DMA | -0.2% | -25.0% |
| 3M | 1YR | |
| Volatility | 98.5% | 82.7% |
| Downside Capture | 1.13 | 1.33 |
| Upside Capture | -20.62 | 132.91 |
| Correlation (SPY) | 26.6% | 28.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.25 | 2.87 | 2.07 | 2.39 | 1.21 | 1.42 |
| Up Beta | 1.83 | 4.97 | 7.45 | 4.65 | 0.83 | 1.17 |
| Down Beta | 1.57 | 3.06 | 1.54 | 2.12 | 0.98 | 1.96 |
| Up Capture | 286% | 374% | -28% | 192% | 145% | 175% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 16 | 23 | 58 | 115 | 337 |
| Down Capture | 237% | 164% | 206% | 175% | 155% | 108% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 11 | 22 | 35 | 62 | 126 | 370 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRDF | |
|---|---|---|---|---|
| CRDF | -39.8% | 83.1% | -0.22 | - |
| Sector ETF (XLV) | 12.0% | 15.9% | 0.52 | 35.7% |
| Equity (SPY) | 26.7% | 12.5% | 1.77 | 29.1% |
| Gold (GLD) | 38.9% | 27.4% | 1.19 | 0.3% |
| Commodities (DBC) | 23.5% | 16.2% | 1.32 | -9.5% |
| Real Estate (VNQ) | 15.6% | 13.6% | 0.82 | 26.9% |
| Bitcoin (BTCUSD) | -12.8% | 42.6% | -0.21 | 23.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRDF | |
|---|---|---|---|---|
| CRDF | -28.0% | 99.2% | 0.11 | - |
| Sector ETF (XLV) | 5.6% | 14.6% | 0.20 | 22.7% |
| Equity (SPY) | 10.5% | 17.1% | 0.48 | 26.2% |
| Gold (GLD) | 21.5% | 17.8% | 0.99 | 3.2% |
| Commodities (DBC) | 10.7% | 18.8% | 0.47 | 1.2% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 23.6% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 20.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRDF | |
|---|---|---|---|---|
| CRDF | -42.0% | 105.9% | -0.03 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 18.7% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 20.4% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | 2.1% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 5.0% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 15.7% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 11.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -2.7% | -4.4% | 7.1% |
| 5/8/2025 | 1.1% | 4.6% | 46.8% |
| 2/27/2025 | 4.4% | -4.4% | -19.0% |
| 11/7/2024 | -24.7% | -30.6% | -40.3% |
| 8/8/2024 | 11.7% | 12.2% | 8.5% |
| 2/29/2024 | 64.9% | 98.9% | 224.6% |
| 11/2/2023 | -2.6% | -14.0% | 13.2% |
| 8/9/2023 | 8.4% | -1.0% | -3.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 7 | 13 |
| # Negative | 6 | 13 | 7 |
| Median Positive | 5.7% | 14.8% | 13.2% |
| Median Negative | -3.8% | -5.8% | -13.3% |
| Max Positive | 64.9% | 98.9% | 224.6% |
| Max Negative | -24.7% | -30.6% | -40.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2027 Cash Runway | |||||||
Prior: Q1 2025 Earnings Reported 5/8/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | |||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.